Vnitřní lékařství 6/2020

PŘEHLEDOVÉ ČLÁNKY Histiocytózy a neoplazie odvozené od makrofágů a dendritických buněk. Srovnání WHO klasifikace z roku 2017 a klasifikace Histiocyte society z roku 2016 | E27  / Vnitř Lék 2020; 66(6): e19–e27  /  VNITŘNÍ LÉKAŘSTVÍ www.casopisvnitrnilekarstvi.cz 34. Higgins LS, Go RS, Dingli D, et al. Clinical Features and Treatment Outcomes of Pati- ents With Necrobiotic Xanthogranuloma Associated With Monoclonal Gammopathies. Clin Lymphoma Myeloma Leuk 2016; 16: 447–452. 35. Hilal T, DiCaudo DJ, Connolly SM et al. Necrobiotic xanthogranuloma: a 30-year single­ ‑center experience. Ann Hematol 2018; 97: 1471–1479. 36. Sagiv O, Thakar SD, Morrell G, et al. Rituximab Monotherapy Is Effective in Treating Orbital Necrobiotic Xanthogranuloma. Ophthalmic Plast Reconstr Surg 2018; 34: e24–e27. 37. Jacobsen E, Shanmugam V, Jagannathan J. Rosai‑Dorfman Disease with Activating KRAS Mutation - Response to Cobimetinib. N Engl J Med 2017; 377: 2398–2399. 38. Matter MS, Bihl M, Juskevicius D. Is Rosai‑Dorfman disease a reactve process? De- tection of a MAP2K1 L115V mutation in a case of Rosai‑Dorfman disease. Virchows Arch 2017; 471: 545–547. 39. Hasegawa M, Sakai F, Okabayashi A, et al. Rosai‑Dorfman Disease of the Lung Over- lapping with IgG4-related Disease: The Difficulty in Its Differential Diagnosis. Intern Med 2017; 56: 937–941. 40. Ghawas MS, Ng T, Chen LYC. Confirmed Efficacy of Lenalidomide and Dexamethaso- ne in Unresectable Cutaneous Facial Rosai‑Dorfman‑Destombes Disease Mayo Clin Proc Innov Qual Outcomes 2019; 3: 94–96. 41. Geller S, Busam K, Hamlin PA et al. Treatment of Rosai‑Dorfman disease with oral bexarotene: a case series. J Dermatolog Treat 2018; doi: 10.1080/09546634.2018.1528001. 42. Averitt AW, Heym K, Akers L, et al. Sinus Histiocytosis With Massive Lymphadenopathy (Rosai Dorfman Disease): Diagnostic and Treatment Modalities for this Rare Entity Revisi- ted. J Pediatr Hematol Oncol 2018; 40: e198–e202. 43. Huhn D. Therapy of malignant histiocytosis. Haematol Blood Transfus 1981; 27: 211–216. 44. Kommalapati A, Tella SH, Durkin M, et al. Histiocytic sarcoma: a population‑based analysis of incidence, demographic disparities, and long‑term outcomes. Blood 2018; 131: 265–268. 45. Kommalapati A, Tella SH, Durkin M, et al. Histiocytic sarcoma: a population‑based analysis of incidence, demographic disparities, and long‑term outcomes. Blood 2018; 131: 265–268. 46. Broadwater DR, Conant JL, Czuchlewski DR, et al. Clinicopathologic Features and Cli- nical Outcome Differences in De Novo Versus Secondary Histiocytic Sarcomas: A Multi­ ‑institutional Experience and Review of the Literature. Clin Lymphoma Myeloma Leuk 2018; 18: e427–e435. 47. Voruz S, Cairoli A, Naveiras O, et al. Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma. Haematologi- ca 2018; 103: e39–e41. 48. Iwabuchi H, Kawashima H, Umezu H, et al. Successful treatment of histiocytic sar- coma with cladribine and high‑dose cytosine arabinoside in a child. Int J Hematol 2017; 106: 299–303. 49. Gounder MM, Solit DB, Tap WD. Trametinib in Histiocytic Sarcoma with an Activating MAP2K1 (MEK1) Mutation. N Engl J Med 2018; 378: 1945–1947. 50. Chen T, Gopal P. Follicular Dendritic Cell Sarcoma. Arch Pathol Lab Med 2017; 141: 596–599. 51. Facchetti F, Lorenzi L. Follicular dendritic cells and related sarcoma. Semin Diagn Pathol 2016; 33: 262–276. 52. Jain P, Milgrom SA, Patel KP, et al. Characteristics, management, and outcomes of pati- ents with follicular dendritic cell sarcoma. Br J Haematol 2017; 178: 403–412. 53. Sasaki M, Izumi H, Yokoyama T, et al. Follicular dendritic cell sarcoma treated with a va- riety of chemotherapy. Hematol Oncol 2017; 35: 905–908. 54. Purkait S, Mallick S, Joshi PP, et al. Retroperitoneal and mediastinal follicular dendritic cell sarcoma: report of 3 cases with review of literature. Hematol Oncol 2017; 35: 374–379. 55. Ninkovic S, Cole‑Sinclair MF. Interdigitating dendritic cell sarcoma: diagnostic pit- falls, treatment challenges and role of transdifferentation in pathogenesis. Pathology 2017; 49: 643–646. 56. Nguyen CM, Cassarino D. Primary Cutaneous Interdigitating Dendritic Cell Sarco- ma: A Case Report and Review of the Literature. Am J Dermatopathol 2016; 38: 628–631. 57. Di Liso E, Pennelli N, Lodovichetti G, et al. Braf mutation in interdigitating dendritic cell sarcoma: a case report and review of the literature. Cancer Biol Ther 2015; 16: 1128–1135. 58. Minoia F, Bovis F, Davì S, et al. Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnos- tic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macro- phage Activation Syndrome. J Pediatr 2017; 189: 72–78.e3. 59. Lerkvaleekul B, Vilaiyuk S. Macrophage activation syndrome: early diagnosis is key. Open Access Rheumatol 2018; 10: 117–128. 60. Otrock ZK, Daver N, Kantarjian HM, et al. Diagnostic Challenges of Hemophagocytic Lymphohistiocytosis. Clin Lymphoma Myeloma Leuk 2017; 17: S105–S110. 61. Henter JI, Horne A, Aricó M et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007; 48: 124–131. 62. Šrámek J, Karvunidis T, Lysák D, et al. Hemofagocytární lymfohistiocytóza u dospělých - review a kazuistika. Vnitř Lék 2018; 64: 300–307 63. La Rosée P, Horne A, Hines M, et al. Recommendations for the management of hemo- phagocytic lymphohistiocytosis in adults. Blood 2019; doi: 10.1182/blood.2018894618. 64. Bergsten E, Horne A, Aricó M, et al. Confirmed efficacy of etoposide and dexametha- sone in HLH treatment: long‑term results of the cooperative HLH-2004 study. Blood 2017; 130: 2728–2738. 65. Risma KA, Marsh RA. Hemophagocytic Lymphohistiocytosis: Clinical Presentations and Diagnosis. J Allergy Clin Immunol Pract 2019; 7: 824–832. 66. Daver N, McClain K, Allen CE, et al. A consensus review on malignancy‑associated he- mophagocytic lymphohistiocytosis in adults. Cancer 2017; 123: 3229–3240. 67. Zandvakili I, Conboy CB, Ayed AO, et al. Ruxolitinib as first‑line treatment in seconda- ry hemophagocytic lymphohistiocytosis: A second experience. Am J Hematol 2018; doi: 10.1002/ajh.25063. 68. Cuglievan B, Miranda RN. Kikuchi‑Fujimoto disease. Blood 2017; 129: 917–918.